PMN

ProMIS Neurosciences Inc

Add to Watchlist

Advanced Chart

0.391

-0.019(-4.635%)1D

Line

Candle

YTD

High

0.416

Open

0.4124

VWAP

0.40

Vol

458.11K

Mkt Cap

20.66M

Low

0.3794

Amount

183.46K

EV/EBITDA(TTM)

Total Shares

18.96M

17.51M

EV/OCF(TTM)

P/S(TTM)

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.184

-12.21%

-0.249

+1152.16%

-0.288

-193.34%

Estimates Revision

The market is revising No Change the revenue expectations for ProMIS Neurosciences, Inc. (PMN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -33.78%.

EPS Estimates for FY2025

Revise Upward

+5.07%

In Past 3 Month

Stock Price

Go Down

-33.78%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast PMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMN is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.391

Low

3.00

Averages

3.00

High

3.00

Current: 0.391

Low

3.00

Averages

3.00

High

3.00

H.C. Wainwright

Raghuram Selvaraju

initiated

2025-07-14

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

2025-07-14

initiated

Reason

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of ProMIS Neurosciences with a Buy rating and $4 price target. ProMIS is an emerging biotechnology company focused on developing novel therapeutic and vaccine-based approaches to address serious unmet medical needs in neurology, the analyst tells investors in a research note.

Maxim

NULL -> Buy

initiated

2025-05-12

Reason

Maxim

Price Target

2025-05-12

initiated

NULL -> Buy

Reason

Maxim initiated coverage of ProMIS Neurosciences with a Buy rating and $3 price target.

Guggenheim

Eddie Hickman

Strong Buy

Reiterates

2025-04-01

Reason

Guggenheim

Eddie Hickman

Price Target

2025-04-01

Reiterates

Strong Buy

Reason

Guggenheim

Eddie Hickman

Strong Buy

Reiterates

n/a

2025-02-26

Reason

Guggenheim

Eddie Hickman

Price Target

n/a

2025-02-26

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for ProMIS Neurosciences Inc (PMN.O) is -0.46, compared to its 5-year average forward P/E of -1.07. For a more detailed relative valuation and DCF analysis to assess ProMIS Neurosciences Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.07

Current PE

-0.46

Overvalued PE

0.59

Undervalued PE

-2.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.13

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.09

Undervalued EV/EBITDA

-2.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2130.29

Current PS

0.41

Overvalued PS

6511.73

Undervalued PS

-2251.15